{"id":509469,"date":"2020-10-01T18:30:02","date_gmt":"2020-10-01T18:30:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=509469"},"modified":"2020-10-01T18:30:02","modified_gmt":"2020-10-01T18:30:02","slug":"global-oral-biologics-and-biosimilars-market-value-expected-to-reach-23-billion-by-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/global-oral-biologics-and-biosimilars-market-value-expected-to-reach-23-billion-by-2030_509469.html","title":{"rendered":"Global Oral Biologics And Biosimilars Market Value Expected To Reach $23 Billion By 2030"},"content":{"rendered":"
\"Global<\/a><\/p>\n
\n
Oral Biologics And Biosimilars Market<\/div>\n<\/div>\n<\/div>\n
Merck Is One Of The Largest Players In The Oral Biologics And Biosimilars Market, According To The Business Research Company\u2019s Oral Biologics And Biosimilars Market – By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (Insulin, Growth Hormone, Parathyroid Hormone) Modulators, Immunostimulants, Others)<\/div>\n

(Companies Covered: Merck & Co, GlaxoSmithKline, Novo Nordisk, ALK-Abello A\/S, Aimmune Therapeutics, Inc., Henlius)<\/em><\/p>\n

The global oral biologics and biosimilars market reached a value of nearly $3,076.1 million in 2019, having grown at a compound annual growth rate of 6.5% since 2015, and is expected to grow at a compound annual growth rate of 17.1% to nearly $5,787.9 million by 2023. Also, the market is expected to growth to $8,687.7 million in 2025 at a compound annual growth rate of 22.5% and to $23,585.5 million in 2030 at a compound annual growth rate of 22.1%.<\/p>\n

Read More On The Global Oral Biologics And Biosimilars Market Report At – <\/strong><\/p>\n

https:\/\/www.thebusinessresearchcompany.com\/report\/oral-biologics-and-biosimilars-market<\/a><\/p>\n

The oral biologics and biosimilars market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, and cancer. <\/p>\n

Global Oral Biologics And Biosimilars Market Segmentation –<\/strong><\/p>\n

1)By Therapeutic Mechanism –<\/strong> Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants and Others.<\/p>\n

2)By Disease –<\/strong> Diabetes, Arthritis & Chron`s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases, Others Diseases.<\/p>\n

3)By Molecule Type –<\/strong> Vaccines, Proteins & Peptides, Monoclonal Antibodies and Others.<\/p>\n

4)By Distribution Channel –<\/strong> Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.<\/p>\n

Global Oral Biologics And Biosimilars Market Driver –<\/strong><\/p>\n

Technology is expected to be a continued driver of market growth during this period. An area of particular development is likely to be physiology simulation modeling. Markets such as this one will benefit from the greater efficiencies offered by developments in this area.<\/p>\n

Request For A Sample Of The Global Oral Biologics And Biosimilars Market Report At – <\/strong><\/p>\n

https:\/\/www.thebusinessresearchcompany.com\/sample.aspx?id=3361&type=smp<\/a><\/p>\n

Few Points From The Global Oral Biologics And Biosimilars Market TOC<\/strong><\/p>\n

1. Oral Biologics & Biosimilars Market Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
6. Introduction
6.1.1. Segmentation By Geography
6.1.2. Segmentation By Disease
7. Oral Biologics & Biosimilars Market Characteristics
7.1. Market Definition
7.2. Market Segmentation By Disease
8. Oral Biologics And Biosimilars Market, Supply Chain Analysis
8.1. Raw Material Suppliers
8.2. Contract Research Organization (CRO)
9. Oral Biologics & Biosimilars Market Product Analysis – Product Examples
10. Oral Biologics & Biosimilars Market, Product Pipeline Analysis<\/p>\n

Interested to know more about The Business Research Company? <\/strong><\/p>\n

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> The Business Research Company<\/a>
Contact Person:<\/strong> Oliver Guirdham
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +44 20 7193 0708
Address:<\/strong>
City:<\/strong> London
State:<\/strong> Greater London
Country:<\/strong> United Kingdom
Website:<\/strong> https:\/\/www.thebusinessresearchcompany.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Oral Biologics And Biosimilars Market Merck Is One Of The Largest Players In The Oral Biologics And Biosimilars Market, According To The Business Research Company\u2019s Oral Biologics And Biosimilars Market – By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-509469","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/509469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=509469"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/509469\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=509469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=509469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=509469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}